Piramal Pharma Q1 FY27 Results (NSE: PPLPHARMA)
Signal: Loss narrowed
The read
Consolidated Q1FY27 shows a stark standalone-subsidiary divergence: the standalone business continues to grow revenue (+16% YoY) and deliver stable profit (~₹113 Cr PAT), but the group remains loss-making (₹69 Cr loss) because 11 unaudited subsidiaries collectively lost ₹146.02 Cr after tax in the quarter. The gross margin collapse at the group level (down 1159bps YoY) signals severe input-cost pressure in the overseas CDMO/critical care businesses, which the standalone's modest raw-material improvement cannot offset. The good news: operating loss narrowed to just ₹7 Cr before associate income (vs ₹100 Cr loss in Q1FY26), suggesting the subsidiaries' cost structure is improving from a very low base. The trajectory hinges on whether the subsidiaries can sustain narrowing losses and eventually return to profitability — without a turnaround there, the group remains value-destructive.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2,269.92 Cr | 17.4% | -17.5% |
| EBIT | ₹295.23 Cr | -17.5% | |
| Net profit | ₹-69.39 Cr | 15.1% | |
| EPS | ₹-0.52 | 16.1% | |
| EBIT margin | 13.01% |
P&L walk
Revenue grew 17.4% YoY to ₹2,269.92 Cr, but gross margin collapsed by 1159bps YoY to 37.56% (raw material + purchased stock + inventory change spiking to ₹852.27 Cr vs ₹694.05 Cr in Q1FY26) — a severe input-cost headwind that overwhelmed the topline growth. OPM fell 272bps YoY to 13.01%, dragged by gross margin erosion, though employee cost % improved 219bps YoY. Net loss narrowed to ₹69.39 Cr from ₹81.70 Cr loss last year, helped by a ₹3.42 Cr deferred tax credit and absence of exceptional items (vs ₹196.14 Cr exceptionals in FY26 full year). The group remains loss-making at the operating line (EBIT loss of ₹27.02 Cr before associate share).
Key positives
- Standalone revenue grew 16.0% YoY to ₹1,124.95 Cr, indicating strong domestic formulations/API demand.
- Standalone PAT stable at ₹113.48 Cr despite higher tax expense — core business profitable.
- Consolidated operating loss before exceptional items narrowed sharply from -₹99.76 Cr in Q1FY26 to -₹7.46 Cr in Q1FY27, signaling subsidiary cost improvement.
- Finance costs at standalone dropped 29.6% YoY to ₹16.36 Cr, reflecting lower debt burden.
- No exceptional items this quarter vs ₹196 Cr exceptionals in prior full year — clean result.
Key concerns
- Consolidated gross margin collapsed by 1159bps YoY to 37.56%, driven by surge in raw material + purchased stock costs (₹1,145.01 Cr vs ₹694.05 Cr in Q1FY26).
- Group still posted net loss of ₹69.39 Cr, the 8th consecutive quarterly loss on a consolidated basis in the last 12 quarters.
- 11 unaudited subsidiaries contributed revenue of ₹1,364.40 Cr but a net loss of ₹146.02 Cr — the CDMO/critical care businesses abroad are deeply unprofitable.
- Consolidated OPM contracted 272bps YoY to 13.01%, far below standalone's 19.84% — group margin profile structurally impaired by subsidiaries.
- Revenue QoQ declined 17.5% from Q4FY26 (₹2,751.77 Cr), but this is seasonal following Q4 year-end high base.
Research and educational content only. Not investment advice.